Article
Gastroenterology & Hepatology
Makoto Naganuma, Kenji Watanabe, Satoshi Motoya, Haruhiko Ogata, Toshiyuki Matsui, Yasuo Suzuki, Lyann Ursos, Shigeru Sakamoto, Mitsuhiro Shikamura, Tetsuharu Hori, Jovelle Fernandez, Mamoru Watanabe, Toshifumi Hibi, Takanori Kanai
Summary: This study aimed to evaluate the efficacy and safety of vedolizumab treatment with or without concurrent immunomodulator use in Japanese patients with moderate-to-severe ulcerative colitis. The results suggested that concurrent immunomodulator use may benefit in maintaining the clinical efficacy of vedolizumab without significantly increasing the incidence of infections.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Julien Kirchgesner, Rishi J. Desai, Maria C. Schneeweiss, Laurent Beaugerie, Sebastian Schneeweiss, Seoyoung C. Kim
Summary: Combination therapy with vedolizumab and thiopurines is associated with a lower risk of treatment failure compared to vedolizumab monotherapy in patients with CD, but the effect is less pronounced in UC.
Article
Biochemistry & Molecular Biology
Keiichi Haga, Tomoyoshi Shibuya, Taro Osada, Shunsuke Sato, Yuka Fukuo, Osamu Kobayashi, Toshio Yamada, Daisuke Asaoka, Kentaro Ito, Kei Nomura, Mayuko Haraikawa, Osamu Nomura, Hirofumi Fukushima, Takashi Murakami, Dai Ishikawa, Mariko Hojo, Akihito Nagahara
Summary: This study found that VDZ is effective in the majority of UC patients, with a high rate of mucosal healing even in those who have previously failed biological therapy. Early clinical remission can predict long-term remission, and week 6 can be a useful evaluation point when using VDZ for UC treatment.
Article
Gastroenterology & Hepatology
Einat Ritter, Ayal Hirsch, Naomi F. Isakov, Yulia Ron, Nathaniel A. Cohen, Nitsan Maharshak
Summary: This study found that higher adalimumab levels are associated with clinical remission, biomarker normalization, and endoscopic remission. An adalimumab level of >= 8.25 mu g/mL is associated with deep remission, providing additional data to guide therapeutic drug monitoring with adalimumab.
JOURNAL OF CLINICAL GASTROENTEROLOGY
(2021)
Article
Medicine, General & Internal
Maria Gonzalez-Vivo, Minna K. Lund Tiirikainen, Montserrat Andreu, Agnes Fernandez-Clotet, Alicia Lopez-Garcia, Francisca Murciano Gonzalo, Lourdes Abril Rodriguez, Carmen de Jesus-Gil, Ester Ruiz-Romeu, Lidia Sans-de San Nicolas, Lluis F. Santamaria-Babi, Lucia Marquez-Mosquera
Summary: Baseline circulating CD8 (+) alpha(4)beta(+)(7) memory T cells could serve as an early predictor of remission in patients with ulcerative colitis, helping to select a subset of responders.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Keijiro Numa, Kazuki Kakimoto, Yasuyoshi Tanaka, Noboru Mizuta, Naohiko Kinoshita, Kei Nakazawa, Ryoji Koshiba, Yuki Hirata, Kazuhiro Ota, Takako Miyazaki, Shiro Nakamura, Kazuhide Higuchi, Hiroki Nishikawa
Summary: This study evaluated the efficacy of adalimumab (ADA) for maintaining remission in patients with refractory ulcerative colitis (UC). The results showed that switching to ADA after tacrolimus (TAC) therapy can effectively prevent relapse in these patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Pediatrics
Maria Hemming-Harlo, Laura Merras-Salmio, Anne Nikkonen, Kaija-Leena Kolho
Summary: This study investigated the trough levels of vedolizumab (VDZ) in a pediatric population with inflammatory bowel disease (IBD) in a real-life setting. The results showed that trough levels of VDZ were not associated with clinical remission or continuation of treatment, while a positive response on gut inflammation after induction predicted the need for maintenance therapy.
EUROPEAN JOURNAL OF PEDIATRICS
(2023)
Article
Psychology, Multidisciplinary
Felicitas Engel, Sabrina Berens, Annika Gauss, Rainer Schaefert, Wolfgang Eich, Jonas Tesarz
Summary: The study found that patients with CD/UC have higher levels of depression and anxiety compared to HC, and there are differences in personality functioning in the domain of self-perception and regulation. Minor differences were found in mentalization and attachment between CD/UC and HC.
FRONTIERS IN PSYCHOLOGY
(2021)
Article
Pharmacology & Pharmacy
Merve Sivridas, Rob H. Creemers, Dennis R. Wong, Paul J. Boekema, Tessa E. H. Romkens, Lennard P. L. Gilissen, Adriaan A. van Bodegraven, Floris C. Loeff, Theo Rispens, Luc J. J. Derijks
Summary: The aim of this study was to determine the association between vedolizumab (VDZ) trough concentration and clinical and biochemical remission in the maintenance phase. The results showed no statistically significant correlation between VDZ concentration and clinical remission in all patient groups. However, patients in biochemical remission had higher VDZ trough concentrations. Therefore, there is an association between VDZ concentration and biochemical remission, but not with clinical remission.
Article
Nutrition & Dietetics
Aleksandra Sobolewska-Wlodarczyk, Ewa Walecka-Kapica, Marcin Wlodarczyk, Anita Gasiorowska
Summary: This study suggests that Nutritional Risk Index (NRI), Controlling Nutritional Status (CONUT), and Malnutrition Universal Screening Tool (MUST) could serve as inexpensive and efficient predictive biomarkers for assessing the response to vedolizumab therapy in ulcerative colitis (UC) patients.
Article
Medical Laboratory Technology
Niels Vande Casteele, Lili Yang, Iwona Dobler, Christian Agboton, Teresa McRorie Osborn, Ajit Suri, Dirk Lindner, Glennda M. Smithson
Summary: This study compared the results of 5 commercial assays measuring VDZ concentration and ADA with the reference assays used in VDZ clinical studies, providing clinicians with guidance in interpreting commercial assay results.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Gastroenterology & Hepatology
Carlos Taxonera, Maria Jesus Fernandez-Acenero, David Olivares, Marta Calvo, Begona Casis, Fernando Bermejo, Pilar Lopez Serrano, Marisa Iborra, Francisco Mesonero, Maia Bosca Watts, Cristina Diaz del Arco, Isabel Vera, Sonsoles Olivares, Alicia Algaba, Cristina Alba
Summary: This study investigated the association between golimumab trough concentrations during maintenance and outcomes such as endoscopic healing, histologic remission, and long-term persistence in UC patients. The results showed that golimumab concentrations were associated with favorable treatment outcomes.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Aaron B. Parrish, Nicole E. Lopez, Adam Truong, Karen Zaghiyan, Gil Y. Melmed, Dermot P. B. McGovern, Christina Ha, Gaurav Syal, Nirupama Bonthala, Anjali Jain, Carol J. Landers, Stephan R. Targan, Phillip Fleshner
Summary: This study found that serum vedolizumab levels do not affect postoperative morbidity in patients with IBD, but may help reduce the incidence of postoperative ileus in patients with Crohn's disease.
DISEASES OF THE COLON & RECTUM
(2021)
Article
Gastroenterology & Hepatology
Neeraj Narula, Emily C. L. Wong, John K. Marshall, Jean-Frederic Colombel, Parambir S. Dulai, Walter Reinisch
Summary: For patients with moderate to severe biologic naive UC, infliximab and vedolizumab have similar efficacy in improving clinical symptoms, but infliximab has higher rates of corticosteroid-free clinical remission (CR) and endoscopic remission (ER) after 1 year of treatment.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Alice Burgevin, Benedicte Caron, Alexa Sasson, Amandine Luc, Patrick Netter, Cedric Baumann, Ashwin N. Ananthakrishnan, Laurent Peyrin-Biroulet
Summary: The safety of vedolizumab and ustekinumab therapies in older patients with inflammatory bowel disease was compared. The study found that there was no difference in terms of safety between vedolizumab and ustekinumab in patients with Crohn's disease. The occurrence of adverse events per year of follow-up was also similar between vedolizumab and anti-TNF therapy for ulcerative colitis and Crohn's disease.
JOURNAL OF CLINICAL MEDICINE
(2022)
